Blog – Page 3 – Clinical Trial Results

#SNACKABLEHEALTH with Gibson and Lam:

April 17, 2025

Dr. Lam and Dr. Gibson discuss the consistency of benefits with weight loss independent of GFR in the SUMMIT trial, […]

Dr. Sekar Kathiresan and Dr. C. Michael Gibson discuss “one and done” gene editing for high cholesterol by permanently inhibiting PCSK9 by about 70% to achieve an average LDL lowering of 59%.

April 14, 2025

Disclosures TBD

#ACC2025 Obesity Wrap Up:

April 14, 2025

Dr. Danielle Belardo and Dr. C. Michael Gibson discuss the PRAGUE-25 trial (catheter ablation vs. antiarrhythmics with weight management and […]

#ACC2025 Antithrmbotic / Antiplatelet Wrap Up:

April 11, 2025

Dr. Bhatt and I discuss ticagrelor reversal using bentracimab from the REVERSE-IT trial, as well as comparable efficacy and safety […]

Dr. Xiaojie Xie and Dr. C. Michael Gibson discuss: Efficacy And Safety Of SHR-1918, An Angiopoietin-like 3 Monoclonal Antibody, In Combination With Lipid-lowering Therapy In Patients With Suboptimally Controlled Hyperlipidemia: A Multicenter, Randomized, Double Blind, Placebo-controlled Phase 2 Trial

March 31, 2025

Disclosures: TBD

Dr. Michael J. Koren and Dr. C Michael Gibson discuss: Efficacy And Safety Of Azd0780, An Oral Small Molecule Pcsk9 Inhibitor For Treatment Of Hypercholesterolemia: Results From A Ph2b Randomized Placebo-controlled Clinical Trial

March 31, 2025

Disclosures: TBD

Dr. Marco G. Mennuni and Dr. C. Michael Gibson discuss: Alternative Antithrombotic Pathways In Acute Myocardial Infarction With Large Thrombus Burden: A Randomized Trial ARISE-ARMYDA 7

March 31, 2025

Disclosures: TBD

Dr. Jian-An Wang and I discuss: Comparison Of Angiography-derived Fractional Flow Reserve-guided And Intravascular Ultrasound-guided Percutaneous Coronary Intervention Strategies: The FLAVOUR II Trial

March 31, 2025

Disclosures: TBD

Dr. Marc Humbert and Dr. C. Michael Gibson Discuss: Efficacy And Safety Of Sotatercept In High-Risk Patients With Pulmonary Arterial Hypertension: Results From ZENITH Phase 3 Trial

March 31, 2025

Disclosures: TBD

Dr. Kausik K. Ray and Dr. C. Michael Gibson Discuss: Effect Of Solbinsiran, A Small Interfering RNA Targeting ANGPTL3, On Biomarkers Of Major Adverse Cardiovascular Events In Adults With Mixed Dyslipidemia: A Randomized Phase 2 Trial

March 31, 2025

Disclosures: TBD